QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.104.007823v1 68/1/69    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, R. Articles by Song, Z.-H. Search for Related Content PubMed PubMed Citation Articles by Zhang, R. Articles by Song, Z.-H.

Cysteine 2.59(89) in the Second Transmembrane Domain of Human CB2 Receptor Is Accessible within the Ligand Binding Crevice: Evidence for Possible CB2 Deviation from a Rhodopsin Template

Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky (R.Z., Z.-H.S.); and Department of Chemistry and Biochemistry, University of North Carolina Greensboro, Greensboro, North Carolina (D.P.H., J.B.-N., P.H.R.)

In this study, the sensitivity of the CB2 receptor to methanethiosulfonate (MTS) derivatives was tested, and a native cysteine residue conferring the sensitivity was identified. By incubating human embryonic kidney 293 cells stably transfected with CB2 receptors and MTS derivatives such as MTS ethylammonium (MTSEA), [³H]HU-243 binding was inhibited. Pretreatment of the CB2 receptor with cannabinoid ligands prevented this inhibition, suggesting that MTSEA modification occurred within the binding crevice. To identify the cysteine(s) responsible for the MTSEA sensitivity, 10 CB2 mutants were prepared in which the eight cysteines in transmembrane domains or extracellular loop 2 were mutated to serine or alanine, one at a time or in combination. Five mutants exhibited specific [³H]HU-243 binding, with K_d and B_max values similar to those of wild-type CB2. However, five other mutants had no detectable ligand binding and were not detected on cell membranes by Western blot analysis. Among the five mutants with normal binding, only the sensitivity to MTSEA of the C2.59(89)S mutant was reduced significantly. These data demonstrate that C2.59(89) is the residue that mainly confers the inhibitory effect of MTSEA on ligand binding. Furthermore, the magnitude of the second-order rate constant (1.14 ± 0.28 M^–1s^–1) for the MTSEA reaction with wild-type CB2 suggests that C2.59(89) resides at the margin of the CB2 binding site crevice. The accessibility of C2.59(89) to MTSEA provides experimental evidence for a possible conformational difference between TMH2 of CB2 versus Rho. Modeling studies undertaken to explore the origin of such differences suggest it is possibly caused by the conformational influence of S2.54(84).

Address correspondence to: Zhao-Hui Song, Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40292. E-mail: zhsong{at}louisville.edu

This article has been cited by other articles:

				R. A. Artigas, A. Gonzalez, E. Riquelme, C. A. Carvajal, A. Cattani, A. Martinez-Aguayo, A. M. Kalergis, T. Perez-Acle, and C. E. Fardella A Novel Adrenocorticotropin Receptor Mutation Alters Its Structure and Function, Causing Familial Glucocorticoid Deficiency J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3097 - 3105. [Abstract] [Full Text] [PDF]

				A. Kapur, D. P. Hurst, D. Fleischer, R. Whitnell, G. A. Thakur, A. Makriyannis, P. H. Reggio, and M. E. Abood Mutation Studies of Ser7.39 and Ser2.60 in the Human CB1 Cannabinoid Receptor: Evidence for a Serine-Induced Bend in CB1 Transmembrane Helix 7 Mol. Pharmacol., June 1, 2007; 71(6): 1512 - 1524. [Abstract] [Full Text] [PDF]